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E-cadherin istheprimarycell adhesionmoleculewithintheepithelium,andlossofthisproteinisassociatedwithamoreaggressive
tumour phenotype and poorer patient prognosis in many cancers. Loss of E-cadherin is a deﬁning characteristic of epithelial-
mesenchymaltransition(EMT),a process associatedwithtumourcell metastasis.Wehavepreviously demonstratedanEMTevent
during embryonic stem (ES) cell diﬀerentiation, and that loss of E-cadherin in these cells results in altered growth factor response
and changes in cell surface localisation of promigratory molecules. We discuss the implication of loss of E-cadherin in ES cells
within the context of cancer stem cells and current models of tumorigenesis. We propose that aberrant E-cadherin expression is
a critical contributing factor to neoplasia and the early stages of tumorigenesis in the absence of EMT by altering growth factor
response of the cells, resulting in increased proliferation, decreased apoptosis, and acquisition of a stem cell-like phenotype.
1.E-CadherinProteinStructureand Function
Cadherins are a family of calcium ion-dependent cell
surface glycoproteins that function in cell-cell adhesion. The
cadherin family is divided into classical (Type I) and non-
classical (Type II) subtypes, as well as other categories which
include protocadherins and cadherin-related molecules. The
cadherin family is characterised by the presence of extra-
cellular cadherin (EC) repeats within the ectodomain of
the protein, which vary in number within the family. E-
cadherin is a well-characterised single-pass transmembrane
Type I cadherin that is primarily expressed on epithelial
cells and contains a cytoplasmic domain of 150aa and an
extracellular domain of 550aa containing ﬁve EC repeats,
eachofapproximately110aa[1,2].E-cadherincontributesto
the generation and maintenance of adherens junctions (AJ)
via homophilic (E-cadherin-E-cadherin interaction) and,
most often, homotypic (epithelial-epithelial cell interaction)
cell adhesion (Figure 1). This structure is likely to involve E-
cadherin cis-homodimers binding similar cis-homodimers
on adjacent cells to form transhomodimers, although
the exact mechanism of this interaction is unclear [3].
Type I classical cadherins, which also include N-cadherin,
P-cadherin, and VE-cadherin, possess a Histidine-Alanine-
Valine (HAV) motif within the terminal EC repeat of the
extracellular domain which is an essential cell adhesion
recognition sequence [3]. Although there is some contro-
versy surrounding the precise function of distinct regions of
E-cadherin in cell-cell adhesion, many studies have shown
the HAV domain, located on residues 79–81 of the EC1
domain, to play a key role in its adhesive function by
forming a hydrophobic pocket into which a Tryptophan
residue 2 (Trp2) from an adjacent E-cadherin molecule
can dock. Mutations of Trp2 and the alanine residue of
the HAV domain, W2A and A80I, respectively, have been
shown to abolish trans- but not cis-homodimerisation of
E-cadherin molecules, thus demonstrating the key roles of
these amino acids in the formation of E-cadherin mediated
cell-cell contact [2].
The intracellular region of E-cadherin contains two con-
served regions among the classical Type I and II cadherins,
consisting of a juxtamembrane domain (JMD), also known2 Journal of Oncology
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Figure 1: Diagrammatic representation of homophilic E-cadherin interaction and homotypic cell adhesion within the epithelium. E-cadherin
cis-dimers form transhomodimers with E-cadherin molecules on neighbouring cells to facilitate epithelial integrity. Note that the exact
mechanism of homophilic E-cadherin interaction is unclear. For clarity, only E-cadherin is represented within adherens junctions.
as the membrane proximal cytoplasmic/conserved domain
(MPCD), and a β-catenin binding domain. The β-catenin
binding domain facilitates interaction of E-cadherin with
the actin cytoskeleton via the Cytoplasmic Cell adhesion
Complex (CCC), which consists of β-catenin, α-catenin,
and, possibly, Epithelial Protein Lost In Neoplasm (EPLIN)
[4]( Figure 2). The JMD facilitates binding of p120ctn
which stabilises the CCC by preventing clathrin-mediated
endocytosis [5]. However, this convenient subdivision of
the E-cadherin cytoplasmic domain (JMD and β-catenin
domain) does not reﬂect the complexity of interactions
within these two regions (Figure 3). For example, the
JMD also binds Presenilin 1 which can inhibit p120ctn
binding and facilitate cleavageof the E-cadherin cytoplasmic
domain (via γ-secretase) leading to disassembly of AJs.
The β-catenin interacting region of E-cadherin also binds
several other proteins. For example, the type Iγ phos-
phatidylinositol phosphate kinase (PIPKIγ) binding domain
lies within the β-catenin binding site [6]. PIPKIγ binds
preferentially to dimerised E-cadherin and is responsible
for the conversion of phosphatidylinositol phosphate (PIP)
to phosphatidylinositol-4,5-bisphosphate (PIP2)[ 6]. Protein
Tyrosine Phosphatase-μ interacts with the C-terminus of E-
cadherin, partly overlapping the β-catenin binding domain,
andisbelievedtoprotectE-cadherinfromtyrosine phospho-
rylation[3].
2.LossofE-Cadherinduring
TumourProgression
Metastatic spread of tumour cells is the primary cause of
death in cancer patients, with epithelial tumours represent-
ing at least 80% of all cancers. Loss of cell surface E-cadherin
protein correlates with increased tumour cell invasion in
the majority of epithelial tumours and is believed to impart
epithelial-mesenchymal transition (EMT) properties to the
cells,allowingincreased motilityandinvasion[1,7].Therole
of E-cadherin as a metastasis repressor is well established [1,
8]. For example, loss of E-cadherin expression in epithelial
cells leads to abrogation of cell-cell contact and increased
motility[8,9],whilstforcedexpressionofE-cadherinprotein
in metastatic tumour cell lines is suﬃcient for reversal
of this phenotype [1, 10]. E-cadherin is known to be
regulated via several unrelated mechanisms. Repression of
E-cadherin transcripts via E-box binding proteins (e.g.,
Snail and Slug) has been described in detail and is also
associated with tumour cell metastasis [8, 11, 12]. MMP-7
and -13 can cleave cell surface E-cadherin protein resulting
in a soluble ectodomain portion of E-cadherin protein
that can act in a paracrine eﬀect to inhibit E-cadherin
function on neighbouring cells [13]. In addition, soluble
E-cadherin fragments have been shown to induce MMP-2,
MMP-9, and MMP-14 expression in lung tumour cells [14].Journal of Oncology 3
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Figure 2: E-cadherin and the Cytoplasmic Cell adhesion Complex.
E-cadherin is stabilised at the cell surface by its link to the
actin cytoskeleton via β-catenin, α-catenin, and, possibly, Epithelial
Protein Lost in Neoplasm (EPLIN). p120ctn stabilises the CCC by
preventing clathrin-mediated endocytosis.
E-cadherin can also be internalised via the c-met receptor
pathway following activation by HGF [15–17].
As well as loss of E-cadherin correlating with increased
metastatic potential of epithelial-derived tumours, both β-
catenin and α-catenin function as transactivating factors,
the former by inhibiting TCF/LEF- and the latter by
inhibitingKaiso-inducedrepression oftargetgenes[4,5,18].
Loss or aberrant expression of α-catenin is also associated
with a malignant phenotype in many cancers [10, 11].
Initial studies by Watabe and colleagues [19] suggested
that cadherin-catenin-mediated adhesion altered growth
kinetics in a lung carcinoma cell line (PC9). Although
these cells express E-cadherin and β-catenin, they do not
express α-catenin and are unable to form cell aggregates
when grown in suspension culture. However, upon trans-
fection of α-catenin, E-cadherin-mediated cell-cell contact
was restored and resulted in altered growth of these cells,
indicating that E-cadherin adhesion may participate either
indirectly or directly in cellular proliferation. Therefore,
aberrant E-cadherin expression can also be induced by
loss of function of cytoplasmic binding partners of the
protein.
In addition to their structural role in cell-cell adhesion,
manycadherinsalsoparticipateinthetransductionofsignals
from the cell membrane to the nucleus [1]. For example, N-
cadherin has been shown to stimulate FGF signalling [20]
whereas VE-cadherin acts as a coreceptor with VEGFR to
facilitate TGFβ signalling [21]. The dual involvement of β-
catenin in formation of the CCC and Wnt signalling has
led to the proposal of a mechanism implicating E-cadherin
in Wnt signal transduction. In this model, E-cadherin
sequesters β-catenin at the cell membrane to prevent Wnt-
induced β-catenin/TCF transactivation [22, 23]. However,
recent studies suggest that β-catenin exists in two separate
functional compartments within the cell which function
independently to maintain CCC integrity or facilitate Wnt-
dependent transactivation [24]. The homophilic binding of
E-cadherin that functions to maintain cell-cell adhesion can
also regulate the action of the Rho family of GTPases via
p120ctn [25,26].Forexample,cadherin engagementhasbeen
shown to inhibit RhoA activity and activate Rac1 [27]. Rho-
GTPases are small G-proteins that mediate cell motility and
proliferation [1]; the dysregulation of which has also been
implicated in tumorigenesis [28].
3.Embryonic StemCells
When cultured under appropriate conditions, embryonic
stem (ES) cells possess the ability to self-renew indeﬁnitely
whilst retaining the pluripotent capacity to diﬀerentiate into
any cell of the adult organism [29]. The pluripotency of
human ES (hES) cells, shared with induced pluripotent stem
(iPS) cells, provides enormous potential for their use in cell
replacement strategies to target disorders that currently lack
a long-term control strategy, such as type 1 diabetes [30]. In
addition, the proliferative properties of these cells provide a
useful model system to study self-renewal mechanisms that
may be applicable to tumorigenesis.
3.1. An Epithelial-Mesenchymal Transition Event Occurs
during ES Cell Diﬀerentiation. Throughout embryogenesis,
cadherins play a key role in the sorting of heterogeneous cell
populationsto allow tissue segregation. The observation that
E-cadherinnullembryosareunabletoformatrophectoderm
epithelium or blastocoel is demonstrative of the crucial
function of E-cadherin in embryo development [31]. The
E-cadherin null mutation is embryonic lethal; however,
derivation of E-cadherin−/− mouse (m)ES cells from E-
cadherin null embryos has allowed the critical role of E-
cadherinindevelopmentto bedissected inmore detail.EMT
in epiblast cells allows their ingression within the primitive
streak [1],andthemorphologicalchangestothesecellsoccur
concomitantly with a shift from E-cadherin to N-cadherin
expression at the cell surface [32].
Weand others haveshown that an EMT-likeeventoccurs
during ES cell diﬀerentiation [33–36]. Our data described
an E- to N-cadherin switch during ES cell diﬀerentiation in
monolayerculturewhichwasassociatedwithupregulationof
the E-cadherin repressor proteins, Snail, Slug, and SIP1 [33,
34].Inaddition, expression ofMMP-2 and -9transcripts was
induced during this period which correlated with increased
gelatinase activity and cellular motility [33, 34]. Therefore,
diﬀerentiation of ES cells is associated with an EMT event
that is similar to that observed during early embryogenesis.4 Journal of Oncology
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Figure 3: Protein binding sites within the intracellular region of E-cadherin. The cytoplasmic domain of E-cadherin contains binding sites
for a variety of signalling molecules, thus facilitating its role in signal transduction. Abbreviations: S: signal peptide, PRO: propeptide, EC:
extracellular domain, TM: transmembrane domain, N: N-terminus, C: C-terminus, β-cat: β-catenin, HAV: histidine-alanine-valine, BD:
binding domain, PS1: presenilin 1, PIPKIγ:t y p eI γ phosphatidylinositol phosphate kinase, PTPμ: protein tyrosine phosphate μ, AA: amino
acid, CK: casein kinase, PKD: protein kinase D. Adapted from Van Roy and Berx [3].
However, it should be noted that the process of EMT in ES
cells is a predetermined event similar to that which occurs
during early embryogenesis. In contrast, oncogenic EMT
is likely to be a more complex and variable phenomenon.
Indeed,theconceptofoncogenicEMTremainsacontentious
issue since the study of this process during tumorigenesis in
vivo is diﬃcult, relying instead upon indirect observations
or in vitro analysis of tumour cell lines which may not reﬂect
the underlying physiology of the disease. Furthermore, there
is recent evidence that tumourcells can spread in the absence
of EMT [37, 38]. Thus, oncogenic EMT is unlikely to reﬂect
a predetermined event and may well be inﬂuenced by the
underlying genetics and age of the host, genetic instability
of individual tumour cells, the organ in which the tumour
originates, and the microenvironment. However, our studies
in ES cells have allowed the function of loss of E-cadherin to
be examined in detail. Below, we discuss our ﬁndings which
demonstrate that loss of E-cadherin alone does not induce
an EMT event in ES cells and relate this to observations in
tumour cell lines in vitro.
We investigated the function of E-cadherin and N-
cadherin in mES cells by utilising knockout ES cell lines
[34]o ra b r o g a t i o no fE - c a d h e r i nf u n c t i o ni nh E Sc e l l s
using a neutralizing antibody (nAb). In both mES and
hES cells, we observed that absence of E-cadherin activity
resulted in loss of cell-cell contact and increased motility;
however, the cells remained pluripotent and subsequent
removal of the E-cadherin nAb led to reversion of the cells
to a characteristic ES cell phenotype. Therefore, abrogation
of E-cadherin-mediated cell-cell contact in ES cells can
be a reversible event, as also observed in epithelial cell
lines [39], which does not aﬀect pluripotency of the cells.
More importantly, abrogation of E-cadherin mediated cell-
cell contact in both mES and hES cells did not induce
a characteristic EMT-event, suggesting that loss of cell-
cell contact alone is insuﬃcient to promote EMT in these
cells [33, 34]. We also demonstrated in mES cells that E-
and N-cadherin are independently regulated during ES cell
diﬀerentiation and the latter does not induce expression of
EMT-associated transcripts and proteins, although absence
of N-cadherin did signiﬁcantly reduce cellular motility.
Therefore, whilst cadherins are critical components of ES
cell EMT, they do not directly regulate this process and
loss of E-cadheirn alone is insuﬃcient to induce such an
event. Interestingly, this may also be the case in tumours of
epithelial origin. For example, Andersen and colleagues [40]
found that short-term inhibiti onofE - ca dh eri ne xpr es s i oni n
A431 cellsdid not induce an EMT event.They suggested that
the onset of EMT in tumour cells via functional inhibition of
E-cadherin is a slow and gradual process which is associated
with protracted genetic reprogramming of tumour cells.
Therefore, studies in both ES and tumour cell lines suggest
thatlossofE-cadherin aloneisinsuﬃcient toinduceanEMT
event.
Loss of E-cadherin in ES cells, and other epithelial
cells [39], can induce major changes in cellular architecture
and localisation of plasma membrane-associated proteins.
For example, abrogation of E-cadherin function in ES cells
resulted in loss of cortical actin cytoskeleton arrangement
and induction of cell polarization [33, 34]. Furthermore, we
observed that in both mES and hES cells the trophoblast
glycoprotein (5T4 antigen), which is a promigratory factor,
was translocated from the cytoplasm to the plasma mem-
brane in an energy dependent manner within 15 minutes
of exposure of the cells to an E-cadherin nAb. Removal of
the E-cadherin nAb from mES and hES cells resulted in
restoration of cell-cell contact and absence of 5T4 antigen
from the cell surface within 24h. Interestingly, whilst forcedJournal of Oncology 5
expression of E-cadherin protein in E-cadherin−/− ES cells
restored cell-cell contact and reduced motility, the 5T4
antigen remained at the cell surface. 5T4 is a transmembrane
glycoprotein that is upregulated on many carcinomas, and
its expression correlates with poorer clinical outcome in
ovarian, gastric, and colorectal cancers [41–45]. Forced
expression of 5T4 in epithelial cells resulted in increased
motility and loss of E-cadherin-mediated cell-cell contacts
[46]. Therefore, our observations of 5T4 antigen and E-
cadherin expression in ES cells is also reﬂected in epithelial
cell lines.
We have also observed that loss of E-cadherin function
in ES cells results in altered cell surface localisation of
proteoglycans, which are important in basement membrane
formation (Soncin et al., unpublished data). In addition,
microarray analysis of E-cadherin−/− ES cells revealed 2265
transcript alterations compared to wild-type (wt)ES cells,
with eﬀects conﬁned not only to cell adhesion and motility
but also aﬀecting genes associated with primary metabolic
processes, catabolism, apoptosis, and diﬀerentiation (Soncin
et al., unpublished data). Therefore, our data suggests that
t h ef u n c t i o no fE - c a d h e r i ni nE Sc e l l si sn o tm e r e l yt o
maintain cell-cell adhesion but also to regulate transcription
associated with a diverse range of cell functions, maintain
appropriate growth factor responsiveness of the cells, and
retainplasma membranelocalisationofarangeofmolecules.
There are limited studies on the implication of loss of E-
cadherin alone in normal epithelial cells in vivo or in vitro,
and current evidence is predominantly histopathological
analysis of tumour biopsies and in vitro analysis of tumour
cell lines. Histopathological evidence for loss of E-cadherin
in metastatic progression is well established; however, such
analysis does not inform us of the molecular mechanisms
underlying this process nor whether a true EMT event has
occurred. In addition, most studies on loss of E-cadherin in
tumour cell lines involve stimulation of EMT via exogenous
compounds, such as Transforming Growth Factor-β [47],
Interleukin-6 [48], Hepatocyte Growth Factor [49], and
Tumour Necrosis Factor [50]. As such, there is limited
evidence for the function of E-cadherin alone in normal
epithelium. Furthermore, there is scant data assessing the
expression of E-cadherin in early neoplasms, mainly due
to diﬃculties of analysis in vivo. Therefore, the role of
loss of E-cadherin in the formation and establishment of
neoplasms is unclear. In addition, there is some debate as
to whether neoplasms occur as a result of genetic/epigenetic
alterations or whether these changes derive from selection of
proliferating cells (see Somatic Mutation Theory and Tissue
Organisation and Field Theory below). In our opinion,
current theories of tumorigenesis do not provide suﬃcient
explanation for the events leading to the establishment of a
neoplasm nor the function of E-cadherin expression during
this process. Since ES cells are karyotypically normal, they
may aﬀord a more appropriate model for studying the early
stages of neoplasm formation within epithelium, and this is
discussed later in this review.
3.2. E-Cadherin Regulates Growth Factor Signalling in ES
Cells. In order to maintain pluripotency, mES cells require
signals to inhibit diﬀerentiation (Figure 4). The ﬁrst of
these signals to be identiﬁed was leukaemia inhibitory
factor (LIF [51]), an interleukin-6 family cytokine that
binds a heterodimeric complex of gp130 and the LIF
receptor β subunit (LIFR). Gp130 is activated upon LIF
engagement, triggering a number of signal transduction
networks including the Janus kinase (Jak)/Signal Transducer
and Activator of Transcription 3 (STAT3) pathway and the
PI3K/Akt cascade [52, 53]. The Jak/STAT3 and PI3K/Akt
pathways have recently been linked to components of the
“core circuitry” of pluripotency, sex determining region y-
box 2 (Sox2), and Nanog proteins, via Kr¨ uppel-like factor-
4 (Klf4) and the T-box transcription factor Tbx3 [52]
(Figure 4). Bone morphogenetic proteins (BMPs) present
within serum in the culture medium were later shown to
inhibit neuroectoderm lineage speciﬁcation, with mES cells
shown to self-renew in serum-free medium containing LIF,
Bmp4, and N2/B27 supplements [54]. It has subsequently
been demonstrated that mES cells can be cultured in the
absence of LIF and Bmp4 in medium supplemented with
antagonists/agonists of the FGF, ERK, and Wnt pathways
[55].
Whilst E-cadherin−/− ES cells can be cultured in vitro
as pluripotent cells [34] in media supplemented with foetal
bovine serum (FBS) and LIF, we later discovered that
the cells do not utilise LIF under these conditions [56].
Instead, E-cadherin−/− ES cells maintain pluripotency via
the Activin/Nodal pathways whilst optimal proliferation
(self-renewal) is achieved via Fibroblast growth factor-
2( F g f - 2 )( Figure 5(a)). Addition of an FGFR1 inhibitor
(SU5402) to wild-type (Figure 5(b)) or Ecad−/− ES cells
(Figure 5(c)) demonstrated the reliance of the latter cells
for self-renewal via this pathway. The presence of Activin,
Nodal, and Fgf2 in the FBS used for ES cell culture is likely
to reﬂect the ability of E-cadherin−/− ES cells to self-renew
in the absence of LIF. Further analysis of E-cadherin−/−
ES cells demonstrated that these cells could proliferate
in serum-free medium supplemented with Activin/Nodal
and Fgf-2, with exposure to SB431542, an inhibitor of
Activin-like kinase receptors (Alks)-4, -5, and -7, inducing
loss of the pluripotency markers Oct4 and Nanog [56].
Forcedexpression offull-lengthE-cadherin inE-cadherin−/−
ES cells restored cell-cell contact and LIF-dependent self-
renewal via Stat3 signalling [56]. Reversible Activin/Nodal-
mediated pluripotency was also observed in wtES cells
treated with an E-cadherin homodimerisation-inhibiting
peptide, CHAVC, which is likely to target the HAV domain
or Trp2. Interestingly, cells treated with the E-cadherin nAb
DECMA-1 did not exhibit LIF-independent pluripotency,
suggesting that speciﬁc regions of E-cadherin protein reg-
ulate this eﬀect and it is not simply due to loss of cell-cell
contact. Furthermore, Ecad−/− ES cells can also maintain
pluripotency in serum free medium supplemented with LIF,
Bmp4, and N2/B27 demonstrating that these cells possess
a functional “ground state” pluripotent signalling pathway
(as described by Ying et al. [57]), as well as the ability
to circumvent this pathway by utilising Activin and Nodal.
Further evidence for the role of E-cadherin in mES cell self-
renewal has been demonstrated in FAB-SCs, mouse stem6 Journal of Oncology
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Figure 4: LIF signal transduction in mouse ES cells. Following the binding of LIF to the heterodimeric LIFR/gp130 complex, the Jak/STAT3
and PI3K/Akt signallingpathways are activated which regulate expression of Sox2 and Nanog via Klf4 and Tbx3, respectively.
cells derived using Fgf2, Activin, and BIO [58]. In this
study, FAB-SCs exhibited limited chimaerism, but when
cultured in LIF-containing medium, this was restored and
subsequent repression of E-cadherin in these cells induced
diﬀerentiation. Therefore, E-cadherin functions in ES cells
to regulate pluripotency via Jak/Stat3 signalling. It has been
reported that Stat3 can be activated through homophilic
interactions ofE-cadherin in mouse mammary epithelialcell
lines [59]. In this study, the authors plated cells onto surfaces
coated with fragments encompassing the two outermost
domains of E-cadherin and demonstrated activation of
Stat3, even in the absence of direct cell-to-cell contact.
Therefore, regulation of Stat3 signalling pathways by E-
cadherin has been demonstrated in both ES and epithelial
cells.
To investigate the region of E-cadherin responsible for
LIF-dependent pluripotency in mES cells, we utilised cDNA
exhibiting truncated regions of the E-cadherin cytoplasmic
d o m a i na n de x p r e s s e dt h ep r o t e i ni nE - c a d h e r i n −/− ES cells.
E-cadherin−/− mES cells expressing E-cadherin lacking the
terminal 71 amino acids of the cytoplasmic region, which
includesthe β-catenin binding domain, maintained pluripo-
tency via the Activin/Nodal pathway whereas wild-type E-
cadherin protein restored LIF-dependent pluripotency [56].
This data suggests that the E-cadherin/β-catenin complex
is responsible for LIF-dependent pluripotency of mES cells.
This conclusion is corroborated by the observation that
β-cateninnullmEScellsalsoexhibitActivin/Nodal-mediated
self-renewal, irrespective of E-cadherin protein expression
[56].
In human ES cells, TGFβ family signalling has been
shown to be critical for maintenance of pluripotency and
self-renewal (Figure 5(a)). When bound to their dimeric
Activin-likekinase(Alk)receptors,ActivinandNodalinitiate
a signalling cascade involving the phosphorylation of Smads
2a n d3w h i c hs u b s e q u e n t l yf o r mac o m p l e xw i t hS m a d 4
allowing translocation to the nucleus, cofactor binding,
and activation of target genes [60], including Nanog [61].
Speciﬁcally, Activin/Nodalsignalling via Smad2/3is required
to maintain hES cell pluripotency, with FGF2 acting as
a competence factor for Activin/Nodal signal transduction
[62]. This is similar to our observations in E-cadherin−/−
ES cells, suggesting that E-cadherin protein expression levels
function to determine pluripotent signalling pathways in
ES cells.
MouseEScellslackingafunctional E-cadherin/β-catenin
complex, therefore, resemble the self-renewal properties of
hES cells, FAB-SCs, and mouse epiblast-derived stem cells
(EpiSCs). Interestingly, E-cadherin has been shown to be
downregulated in EpiSCs in comparison to wtES cells [63].
It therefore appears that low levels of E-cadherin in mouse-
derived pluripotent cells correlate with Activin/Nodal-
mediated self-renewal whereas higherlevelsofexpression are
associated with LIF-dependent maintenance of pluripotencyJournal of Oncology 7
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Figure 5: Fgf2 and Activin/Nodal signal transduction in mouse E-cadherin−/− ES cells. (a) E-cadherin−/− ES cells maintain pluripotency via
Activin/Nodal signalling and self-renewal through Fgf2 signalling. (b) Wild-type ES cells treated with the FGFR1 small molecule inhibitor
SU5402 exhibit similar proliferation rates compared to control-treated (DMSO) cells. (c) E-cadherin−/− ES cells treated with the FGFR1
small molecule inhibitor SU5402 exhibit signiﬁcantlyreduced proliferation rates compared to control-treated (DMSO) cells.
(Jak/Stat3). We have observed that partial RNA interference
(RNAi) of E-cadherin in mouse ES cells also results in LIF-
independentpluripotency[56]. Nagaoka and colleagues[64]
have demonstrated that E-cadherin-coated tissue culture
plates can decrease the dependence of mES cells to LIF-
dependent self-renewal, although the cells could not be
grown in the absence of this cytokine. We have also observed
that culture of hES cells in the presence of the E-cadherin
nAb SHE78.7 allows culture of the cells in the absence
of FGF-2, even where cell-cell contact is not completely
inhibited (Patent WO2007088372). Therefore, total abro-
gation of E-cadherin-mediated cell-cell contact in ES cells
may not be necessary for altered growth factor response
in these cells, although the underlying mechanisms remain
unknown.
4.TheRoleofE-CadherininRegulatingGrowth
Factor Response during Tumorigenesis and
the Relationshipto ObservationsinESCells
In order for a cell to become cancerous, it must undergo a
series of cellular alterations resulting in increased replicative
potential. Such growth independence may be attributed to
mechanisms in which regulatory pathwaysare perturbedand8 Journal of Oncology
can occur at diﬀering levels of signal transduction. Alter-
ations in growth factor signalling are a predominant feature
of tumour progression; tumour cells secrete elevated levels
of growth factors, which substitute for exogenous growth
factor requirements, or become resistant to physiologically
inhibitory exogenous growth factors. Furthermore, altered
expression at the receptor level or deregulation at the level of
secondary messengers may also contribute to tumorigenesis
[65, 66]. Whilst there are a plethora of growth factors
associatedwithtumorigenesis,forthepurposesofthisreview
we will focus on growth factors that have been associated
with E-cadherin expression.
4.1. Receptor Tyrosine Kinase Family. The ErbB family of
receptor tyrosine kinases (RTKs) are important in main-
taining normal epithelial cell function. RTKs are a diverse
family of receptors that include, amongst others, Epidermal
Growth Factor Receptor (EGFR), Fibroblast Growth Factor
Receptors (FGFR), Vascular Endothelial Growth Factor
Receptor (VEGFR), and Ephrin (Eph) receptors and are
critical signalling components of embryonic development
and adult homeostatic functions [67, 68]. Consequently,
their role in growth factor receptor signalling has resulted in
numerous RTKs being implicated in multiple malignancies
by overexpression of ligand receptors [69]. In particular, the
expression oractivation ofEGFRisaltered in many epithelial
tumours [70], and both EGFR and ErbB2 are validated
targets for cancer chemotherapeutics that are in current use
for treatment of breast, lung, colorectal, and head and neck
cancers [71, 72]. Qian et al. [73]ﬁ r s td e m o n s t r a t e dt h a tE -
cadherin was able to inhibit activation of EGFR in epithelial
cells, demonstrating a bidirectional relationship between
E-cadherin and EGFR. A recent study using recombinant
cadherin ligand assays showed that E-cadherin homophilic
interactions speciﬁcally inhibited EGFR signalling by dis-
rupting the STAT5b signalling pathway [74]. These data
suggest that E-cadherin is able to negatively regulate mito-
genic signalling in tumours mediated by EGFR and that
E-cadherin may have an inhibitory eﬀect on numerous
RTKs, a phenotype observed in many tumours [73, 75, 76].
The dynamic relationship between E-cadherin and EGFR
is interesting since EGFR expression is believed to be an
early event during tumourgenesis [75], whereas E-cadherin
downregulation has been previously associated with later
stages (e.g., EMT).
Utilising E-cadherin−/− ES cells, we have shown that
abrogation of E-cadherin expression alters the cellular
response to the microenvironment and increases prolifer-
ation [56]. Unpublished global gene array analysis of E-
cadherin−/− ES cells in our lab has revealed that a signiﬁcant
proportion of the “top 20” upregulated genes in these cells
areRTKs(Soncinetal.,manuscriptsubmitted).Forexample,
both EphA1 and EGFR transcripts are amongst the “top
ten” upregulated genes in E-cadherin−/− ES cells compared
to the parental cell line. The temporal regulation of EGFR
expression during early stages of tumorigenesis and its
expression following loss of E-cadherin in ES cells supports
our hypothesis (described below) that aberrant regulation
of E-cadherin in epithelial cells alters their response to
exogenous growth factors, resulting in autonomous cell
growth and neoplasm formation in the absence of EMT.
4.2. Transforming Growth Factor β Family. Transforming
growth factor β (TGFβ) signalling is central to many cellular
processes such as cell cycle arrest, angiogenesis, and home-
ostasis, and,as such,itssubsequentroleintumorigenesisand
invasion is complex. TGFβ signal transduction is mediated
via TGFβ1, -β2, -β3, Activin, and Nodal. These ligands bind
to a cell surface receptor complex consisting of a pair of
serine/threonine kinases, TGFβ receptor type I (TGFβR1),
and type II (TGFβR2) [77]. The signal is further propagated
through phosphorylation of Smad proteins. There is signiﬁ-
cant evidence demonstrating a dual role for TGFβ signalling
in both promotion and suppression of tumorigenesis in
a variety of malignancies [78–82]. Of interest is the role
of TGFβ signalling in a subset of cells that possesses
increased tumourigenic capacity. Recent evidence suggests
that this speciﬁc cell population exhibit many features
typical of stem cells, such as self renewal and multipotency,
and have been termed cancer stem cells (CSCs). Activin
receptors exhibit altered expression in cancers [83], and
mice deﬁcient in Inhibin-α (an activin antagonist) develop
tumourswithin four weeks ofbirth [84].Microarray analysis
of E-cadherin−/− ES cells has revealed a number of growth
factors and their receptors that are altered as a consequence
of loss of E-cadherin (Soncin et al., unpublished data) and
that these growth factors and their receptors are similarly
alteredinasigniﬁcantnumberoftumourtypes.Forexample,
BMP4, TGFβ1, and Inhibin-β Ba r ef o u n di nt h e“ t o p
10” genes downregulated in response to abrogation of E-
cadherin compared to wtES cells.
4.3. Fibroblast Growth Factor Family. Studies by Halaban
and colleagues [85] ﬁrst demonstrated a role for autocrine
FGF signalling in tumorigenesis. Melanomas were found to
express high levels of FGF2 and FGFR1, and inhibition of
expression of either of these molecules resulted in inhibition
of tumour cell growth and progression [86], similar to
that observed in mouse E-cadherin−/− ES cells (Figure 5(b))
and hES cells. Moreover, extracellular FGF2 expression con-
tributes to radio- and chemotherapy resistance in multiple
tumour types, further validating the importance of the
tumour cell microenvironment in tumorigenesis [87–89].
Ruotsalainen et al. [90] reported elevated levels of FGF2 in
serum of small cell lung cancer patients, which correlated
with poor prognosis and active angiogenesis, and elevated
expression of FGF2 (amongst others) has been detected in
breastandprostatemalignancies [91,92].HumanEScellsare
dependent upon exogenous FGF2 to maintain pluripotency
in vitro [93], and, in mES cells lacking E-cadherin, Fgf2
is necessary for self-renewal [56]. FGF5 is expressed in
embryonic tissues but scarcely detected in adult tissue;
however, expression of FGF5 and its receptor are associated
with malignancy in astrocytic brain tumours [94]. Although
to date there is no evidence to suggest that E-cadherin
aﬀects FGF5 expression in cancer cells, we have shown that
transcripts for this protein are signiﬁcantly upregulated inJournal of Oncology 9
mouse E-cadherin−/− ES cells compared to wtES cells [56].
This may indicate that the abnormal expression of FGF5
in cancer cells may be due to alterations in E-cadherin
expression in these cells.
In summary, we have shown that growth factors and
their receptors associated with tumorigenesis appear to be
regulated by E-cadherin expression in a similar manner in
epithelial, tumour-derived, and ES cells. In the following
section, we present a hypothesis that dysregulation of E-
cadherin in epithelial tissues is a determining event in
altering growth factor response of the cells leading to
neoplasmformationandsubsequenttumorigenicphenotype
in the absence of EMT.
5.ModelsofTumorigenesis
Three hypotheses have gained signiﬁcant interest in attempt-
ing to explain events leading to tumorigenesis. The Somatic
Mutation Theory (SMT) considers tumorigenesis to be a
multistep evolutionary process where speciﬁc mutations
confer a selective proliferative advantage to a normally qui-
escent cell. By contrast, the Tissue Organisation Field Theory
(TOFT) suggests that tumorigenesis reﬂects organogenesis
“gone awry”, due to tissue disorganisation. The Cancer
Stem Cell Hypothesis (CSCH) suggests that tumorigenesis
results from abnormal proliferation of stem cells leading to
diﬀerentiated transit amplifying cells (TACs) making up the
bulk of the tumour cell mass. SMT relies upon individual
cells exhibiting a default state of quiescence with mutations
in regulatory genes inducing cell proliferation. TOFT is the
antithesis, where cells possess a default state of proliferation
which is controlled by the microenvironment, and, even
where mutations are present, cells will remain established
within a normal tissue until abnormal tissue organisation
occurs.
5.1. Somatic Mutation Theory. SMT remains the prevailing
model for the occurrence of sporadic tumours, which
account for around 95% of all cancers [95]. The theory
suggests that sporadic tumour formation derives from
multiple DNAmutations within a single somatic cell and the
subsequent progeny proliferate to form the tumour mass. As
such, this model dictates that tumorigenesis is the result of
abnormal somatic cell proliferation achieved by mutations
of genes governing cell cycle and proliferation. Whilst this
simple model has many advocates, subsequent research has
gradually undermined some of the core principles of this
theory.Forexample,thelowoccurrenceofgeneticmutations
observed in somatic cells has questioned the relevance of
the SMT model to tumorigenesis since these cannot explain
the high numbers of mutations found in neoplasms [96].
In addition, the isolation of embryonal carcinoma (EC)
cells, derived from teratocarcinomas, has further questioned
the prerequisite of genetic mutations for tumorigenesis.
For example, some EC cell lines, which are the stem cells
of teratocarcinomas, can incorporate normally within the
tissues of mice [97, 98]. Normal function of these chimaeric
mice is dependent upon a low level of EC chimerism,
demonstrating that embryo-derived, karyotypically normal
cells can negatively regulate the proliferative and malignant
phenotype of EC-derived somatic cells. Whilst these obser-
vations do not disprove SMT, they do illustrate that genetic
mutations may not be the primary reason for tumorigenesis
in teratocarcinomas. Thus, the tissue microenvironment is
likely to play a major role in regulating mutated cells to
maintain normal tissue homeostasis.
5.2. Tissue Organisation and Field Theory. TOFT has been
developed by Sonnenschien and Soto [99] and consists of
two default premises: (1) tumorigenesis is a problem of
tissue organisation, comparable to organogenesis during
early development and (2) proliferation is the default state
of all cells. TOFT suggests that carcinogens aﬀect stromal
cells which subsequently results in changes in the microen-
vironment and abnormal organisation of the epithelium,
leading to default proliferation of the cells. In this respect,
the presence of mutations within an epithelial cell will not
result in formation of a neoplasm until disorganisation of
the epitheliumhasoccurred. Indeed,the thesisbehind TOFT
is that carcinogenesis is a “community eﬀect” rather than a
single “cell eﬀect.”
5.3. Cancer Stem Cell Hypothesis. Conventionally, tumours
were viewed according to the principles of the stochastic
model; in that all cells of the tumour were equal in their
proliferative ability and contribution to tumour spread.
Moreover, the clinical implication of this model is that
to successfully treat a tumour all of the cells need to
be removed. The embryonal rest theory of cancer was
ﬁrst proposed by Virchow in 1855 [100–103], suggesting
that tumours arise from dormant embryonic-like cells that
maintain their tumorigenic capacity. This theory is similar
to the current CSCH which, in the last decade, has revealed
new insights in tumour biology by applying the principles
of stem cell biology [80]. Original studies by Lapidot et al.
[104] retrospectively identiﬁed the presence of a subpopu-
lation of cells with a distinct phenotype and functionality
in acute myeloid leukemia. These cells exhibited markers
associated with normal hematopoietic stem cells and had
clonogenic ability upon injection into athymic mice [105].
Subsequent publications have since shown that such cancer
stem cells (CSCs), or side population cells (a semipuriﬁed
group of cancer cells that contain a proportion, but not
solely consisting of, CSCs), have been identiﬁed in many
malignancies including breast, neck, blood, and colon [104,
106–108]. By consensus deﬁnition, a CSC is a cell within
the tumour that possesses the capacity to self-renew and to
produce the heterogeneous lineages of cells that comprise
the tumour [109]. Further evidence for the CSCH can be
observed from the heterogeneity within a tumour, which
is retained by its metastases [105]. This indicates that the
cell(s) responsible for secondary tumours possess a multi-
diﬀerentiative capacity, a feature of stem cells. However,
how does this minor population of cells (typically 0.1-
0.2% of the tumour cell mass) support tumour growth
without being “diluted out” by the tumour cells themselves10 Journal of Oncology
Kelly et al. [110] and Yoo and Hatﬁeld [111]p r o p o s e d
that upon syngeneic transplantation of mouse leukemias a
much larger proportion of the cells contributed to tumour
propagation and that dominant clones, and not rare CSCs,
may sustain many tumours.
5.4. Dysregulation of E-Cadherin and Formation of a Stem
Cell-Like Phenotype. Independent experimental evidence
has suggested that induction of an EMT-event in immor-
talised human mammary epithelial cells (HMECs) results
in acquisition of a stem cell-like phenotype [112], with
multipotency of the cells similar to that observed in
mesenchymal stem cells. EMT was induced in HMECs
by ectopic expression of Snail, Twist, or TGFβ leading to
increased invasion and migration of the cells. However,
since induction of EMT in HMECs will result in altered E-
cadherin expression, it is possible that loss of E-cadherin-
mediatedgrowthfactorresponse ofthecellsmayreﬂectthese
observations, rather than the EMT event itself.
6.Dysregulationof E-CadherininNeoplasia
and Tumorigenesis(DENT) Hypothesis
Below, we discuss our observations of the function of E-
cadherin in ES and somatic epithelial cells in the context of
tumorigenesis to propose a hypothesis termed Dysregulation
of E-cadherin in Neoplasia and Tumorigenesis (DENT). The
DENT hypothesis should not be viewed as an alternative
to current tumorigenesis hypotheses but more as an addi-
tional component of CSCH that attempts to explain events
occurring during the early stages of neoplasia formation.
Our aim is for the DENT hypothesis to stimulate debate
regarding mechanisms associated with neoplasia formation
and subsequent establishment of a tumour cell mass. We
suggest that aberrant E-cadherin expression in epithelial
cells is a decisive factor in the establishment of a neoplasm
by altering growth factor response in the absence of EMT.
We employ the term “aberrant E-cadherin expression” to
include, amongst others, transcript repression and protein
degradation as well as loss of structural integrity via loss of
binding of E-cadherin to the actin cytoskeleton (i.e., altered
β-catenin, α-catenin, p120ctn, or EPLIN expression). We
propose that aberrant E-cadherin expression in an epithelial
cell(s) results in altered growth factor response allowing
the cells to circumvent existing microenvironment growth
factor regulation and, instead, respond to exogenous or
endogenous factors that stimulate proliferation and inhibit
apoptosis. In addition, aberrant E-cadherin expression may
resultintransitionofthecellsintoastemcell-likephenotype.
We suggest that the correlation between loss of E-cadherin
and a more aggressive tumour phenotype in vivo reﬂects a
requirement for the cells to escape growth factor responses
that are inhibitory to cell growth and proliferation, rather
than increased cellular motility per se. Therefore, we propose
thataberrant regulation ofE-cadherin in epithelialcellsleads
to long-term maintenance of a proliferative cancer stem cell-
like phenotype and, as described by Andersen and colleagues
[40], resultsinprotracted geneticreprogramming ofthe cells
subsequentlyleading to EMT and metastasis in later stages of
the disease.
6.1. Evidence for Loss of E-Cadherin in Promoting Neoplasms.
Forced expression of E-cadherin in the gut epithelium
leads to decreased proliferation and increased apoptosis of
epithelial cells [113], suggesting that E-cadherin functions to
maintain epithelial integrity by negatively regulating abnor-
mal cellular growth. In addition, expression of N-cadherin
instead of E-cadherin in the intestinal epithelium of mice
resulted in hyperproliferation of epithelial cells, decreased
apoptosis, and neoplastic formations in the intestinal crypts
[114]. This phenotype was associated with increased Wnt
activity and loss of BMP signalling within the intestine; the
latter of which is similar to that observed in E-cadherin−/−
ES cells. Whilst Libusova and colleagues [114]r e g a r d e dt h i s
observation to be a speciﬁc result of N-cadherin expression,
this eﬀect may also reﬂect absence of E-cadherin in the
intestinal epithelium. Therefore, these observations provide
evidence for the role of loss of E-cadherin in neoplasm for-
mation. We have also observed that inhibition of E-cadherin
expression in ES cells results in increased proliferation of
the cells [56] (Mohamet, unpublished data in hES cells).
It is possible that increased proliferation of epithelial cells,
following aberrant E-cadherin expression, leads to de novo
mutation via selective adaptation. Therefore, it is feasible
that some neoplasms can occur in the absence of inherent
mutations, as observed by Libusova and colleagues [114].
However, for the purpose of this review, we will assume
that epithelial cells already possess the prerequisite genetic
mutations associated with tumorigenesis.
The DENT hypothesis will be discussed below in the
following key stages of tumorigenesis:
(1) neoplasm formation,
(2) establishment of a tumour cell mass,
(3) EMT and metastasis.
(1) Neoplasm Formation. The ﬁrst stage of tumorigenesis is
the formation of a neoplasm, the abnormal proliferation of
cells. We propose that any epithelial cell has the potential
to form a neoplasm; however, this process is inhibited
within normal epithelium by the expression of E-cadherin.
Figure 6(a)showsthatE-cadherinfunctionsinepithelialcells
to enable recognition and responsiveness to antiproliferative
and proapoptotic signals (shown by green arrows and
receptors) and repression of recognition and responsiveness
to proproliferative and antiapoptotic signals (shown by
red arrows). Thus, expression of E-cadherin in epithelial
cells maintains epithelial integrity via appropriate growth
factor recognition and responsiveness. Upon dysregulation
of E-cadherin expression, perhaps via tissue damage, the
epithelial cell circumvents antiproliferative and proapoptotic
signal regulation and, instead, responds to proproliferative
and antiapoptotic stimuli, if present (Figure 6(b), shown
by red receptors on the cell). At this point, the cell may
revert to normal E-cadherin expression and reestablish
within the epithelium (Figure 6(a)). Alternatively, the cellJournal of Oncology 11
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Figure 6: Aberrant E-cadherin expression and neoplasm formation. (a) E-cadherin functions in epithelial cells to enable recognition and
responsiveness to antiproliferative and proapoptotic signals (shown by green arrows and receptors) and repression of recognition and
responsiveness to proproliferative and antiapoptotic signals (shown by red arrows). (b) Upon dysregulation of E-cadherin expression the
epithelial cell circumvents antiproliferative and proapoptotic signal regulation and, instead, responds to proproliferative and antiapoptotic
stimuli, if present (shown by red receptors on the cell). For simplicity, such a cell is referred to as a cancer stem cell (CSC). At this point the
CSC may exhibit restoration of E-cadherin expression, re-establish within the epithelium and lose its stem cell-like phenotype (i.e., return
to the state shown in (a)). (c) The CSC exhibits asymmetric self-renewal leading to formation of TACs which, due to dysregulation of E-
cadherin, fail to participate in normal tissue formation and, instead, form a neoplasm. (d) The CSC and TACs may exhibit restoration of
E-cadherin expression allowing their reestablishment within the epithelium, resulting in a neoplasm of latent tumorigenicity (NLT).
may transform into a stem cell-like phenotype, leading
to formation of TACs which, due to dysregulation of E-
cadherin, fail to participate in normal tissue formation
and, instead, form a neoplasm (Figure 6(c)). For clarity,
we will term a cell exhibiting stem cell-like properties a
“CSC”, although acquisition of this phenotype may be a
protracted process. We further suggest that in early stages
of neoplasia (Figure 6(c)), aberrant E-cadherin expression
is reversible, and, where normal E-cadherin expression is
restored to the CSC, it will reestablish within the epithelium,
lose its stem cell-like phenotype, and form a neoplasm of
latent tumorigenicity (NLT) (Figure 6(d)). In this scenario,
a further event that induces aberrant E-cadherin expression
wouldberequiredtoresume furtherneoplastictissue growth
and, until this event occurs, the cells could persist within the
epithelium without pathological consequence and maintain
normal epithelial integrity. It is important to note that
completeloss ofE-cadherin expression in epithelialcells may
not be necessary to elicit an altered growth factor response.
For example, we have observed that partial knockdown of
E-cadherin in ES cells is suﬃcient to induce altered growth
factor response in these cells [56].
Whilst diﬀerentiated TACs are believed to form the bulk
of a tumour cell mass, there are many reports demonstrating
theisolation ofstemcell-likecellsfromsolidtumours. Often,
these stem cell-like cells, termed CSCs, are isolated as a side
population (SP) from dissociated tumours [106–109], and
rarely represent more than 1% ofthe total tumourcell popu-
lation. The observation that CSCscan be isolated from many
tumours suggests that these cells must exhibit proliferation12 Journal of Oncology
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Figure7:AberrantE-cadherin expressionandformationofalatestageneoplasm.(a)SymmetricalCSCdivisionwithintheearlystageneoplasm
results in multiple CSCs within the neoplastic population. (b) Restoration of E-cadherin expression within the CSCs and TACs leads to
their reestablishment within the epithelium, loss of stem cell-like properties and formation of a neoplasm of latent tumorigenicity. (c)
Alternatively, cellular proliferation continues unabated resulting in a late stage neoplasm comprising CSCs and TACs.
to maintain their presence within the tumour cell mass. The
occurrenceofmultipleCSCswithina tumourderived froma
single CSC can be explained by (1) symmetrical self-renewal
of the CSC or (2) dediﬀerentiation of TACs into a CSC-
likephenotype.Symmetrical self-renewal ofneuralstemcells
has been shown, where a combination of Fgf-2 and Egf
induced niche-independent proliferation of the cells [115].
In addition, a capacity for limited symmetrical self-renewal
ofbreaststemcellshasalsobeendescribed[116].Irrespective
of the mechanism responsible for formation of multiple
CSCs within a population (Figure 7(a)), we suggest that
these cells can also re-establish within the normal epithelium
to form a NLT (Figure 7(b)). Where this does not occur,
cellular proliferation continues unabated resulting in a late-
stage neoplasm formed of the CSCs and TACs (Figure 7(c)).
Therefore, in our model, neoplastic tissue formation is a
reversible event and this may explain the occurrence of
benign neoplasms (NLTs) within the epithelium.
(2) Establishment of a Tumour Cell Mass. We have already
discussed that some EC cell lines can incorporate and
function normally within the tissues of chimaeric mice [97,
98], although this appears to be dictated by the ratio of
normal to EC-derived cells within the animal. For example,
where the ratio of normal- to EC-derived cells is high,
then tissue homeostasis is maintained. However, where this
r a t i oi sl o w ,t h em i c r o e n v i r o n m e n ta p p e a r su n a b l et on e g a -
tively regulate EC-derived cellular proliferation, resulting in
tumorigenesis.Thisislikelytoreﬂecttheratioofantiprolifer-
ative/proapoptotic to proproliferative/antiapoptotic signals
within the microenvironment and the levels of appropriate
receptors on the cells. We expand this observation to our
hypothesis and suggest that where the ratio of antiprolifer-
ative/proapoptotic to proproliferative/antiapoptotic signals
and receptors is high, then a tumour mass will fail to
establish and will remain as a stable neoplasm (Figure 8(a)).
However, where theratio ofantiproliferative/proapoptoticto
proproliferative/antiapoptotic signals and receptors is low,
the microenvironment is no longer capable of positively
regulating tissue homeostasis and the neoplasm becomes
unstable (Figure 8(b)), with the potential for establishment
of a tumour cell mass (Figure 8(c)). It is likely that once
this equilibrium is tipped in favour of aberrant E-cadherin
expression (i.e., a proproliferative/antiapoptoticphenotype),
then the neoplasm becomes an established tumour mass
due to proliferation of the CSCs and TACs. Furthermore,
increased proliferation of CSCs may subsequently lead to
new tumorigenic stem cell niches (TSCN) being formed
from TACs and their progeny which subsequently regulate
CSC proliferation (Figure 8(d)). This scenario explains theJournal of Oncology 13
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Figure 8: Establishment of a tumour cell mass from an early stage neoplasm. (a) Where the ratio of antiproliferative/proapoptotic (green
triangle) to proproliferative/antiapoptotic (red triangle) signals/receptors is high, then a tumour will fail to establish and will remain
as a stable neoplasm (e.g., NLT). (b) An unstable neoplasm forms where the ratio of antiproliferative/proapoptotic to proprolifera-
tive/antiapoptotic signals/receptors is low and the microenvironment is no longer capable of positively regulating tissue homeostasis.
(c) When the microenvironmental signals are tipped in favour of aberrant E-cadherin expression (i.e., a proproliferative/antiapoptotic
phenotype), the neoplasm becomes an established tumour cell mass due to proliferation of the CSCs and TACs. (d) Reorganisation of
the tumour cell mass leads to the formation of new tumorigenic stem cell niches (shown in blue circles) which subsequently regulate CSC
proliferation.
isolation of CSCs from established high cellular mass
tumours, where the expansion of the tumour cell mass
implies the presence of proliferative CSCs. At this point
(Figure 8(d)), dysregulation of E-cadherin expression is
likely to be largely irrelevant to tumour cell growth since
expression of this protein will be under sole control of the
TSCN, and E-cadherin expression may well be required for
establishment and maintenance of the TSCN. Indeed, the
established tumour cell mass is likely to contain both E-
cadherin-positive and -negative cells, with its regulation and
expression under control of the TSCN. Thus, progressive
loss of E-cadherin within a tumour should not be viewed
solely as a consequenceof metastatic potential butalso in the
formation of a neoplasm and the early events leading to the
establishment of a tumour cell mass.
(3) EMT and Metastasis. As we have demonstrated in
ES cells, and by Andersen and colleagues [40] in A431
cells, loss of E-cadherin alone is insuﬃcient to induce
an immediate EMT event; therefore, aberrant E-cadherin
expression in a tumour cell will not necessarily induce
invasion and metastasis. However, absence of E-cadherin
will result in altered growth factor response, and this may
increase the likelihood of cells responding to exogenous or
endogenous factors that can stimulate expression of EMT-
associated molecules, such as MMPs, as well as gradual
genetic reprogramming of the cells [40]. Thus, aberrant
E-cadherin expression within a tumour cell mass is likely
to lead to intensiﬁcation of the metastatic phenotype. For
example, it has been shown that soluble extracellular E-
cadherin fragments can induce a positive feedback loop of
gelatinase expression in lung tumour cells [14]. We have
already discussed the importance of E-cadherin in regulating
epithelial integrity, and it is likely that a metastatic cell will
be dependent on E-cadherin expression for establishment at
a secondary site. This is corroborated by experimental data
showing that secondary tumours derived from carcinomas
often contain cells within the population expressing E-
cadherin[117–119].Therefore,itis possiblethat“successful”
metastatic cells will retain control of E-cadherin regula-
tion rather than exhibiting irreversible epigenetic silencing
or mutation of this gene. This suggests that “successful”
metastatic cells are likely to be CSCs in which E-cadherin
regulation ismaintained (Figure 9).Indeed,itispossible that
E-cadherin expression within a metastatic CSC allows its
establishment within the secondary site and that the process14 Journal of Oncology
Invasive tumour cell mass
Metastasis
Putative CSC
Stroma
Stable neoplasm
Stroma
Unstable neoplasm
Stroma
(a)
(b)
(c)
(d)
Figure 9: Metastasis of CSCs from an invasive tumour. (a) An invasive tumour cell mass results in metastasis of CSCs. (b) A CSC at a
secondary site may exhibit restoration of E-cadherin expression leading to establishment within the epithelium. (c) The CSC may divide
asymmetrically and symmetrically resulting in TACs and CSCs, however, where the ratio of antiproliferative/proapoptotic (green triangle)
to proproliferative/antiapoptotic (red triangle) signals/receptors is high,then a stableneoplasm will form.(d) Alternatively, thepioneer CSC
may maintain aberrant E-cadherin expression resulting in a low ratio of antiproliferative/proapoptotic to proproliferative/antiapoptotic
signals/receptors and formationof an unstable neoplasm with potential for establishmentof a tumour cell mass.
of dysregulation of E-cadherin has to occur once again for
formation of a secondary neoplasm and establishment of
a tumour cell mass (see (1) and (2) above). Therefore,
we suggest that the correlation between loss of E-cadherin
expression and metastasis in epithelial-derived tumours is
a consequence of altered growth factor response which
overcomes antiproliferative and proapoptotic signals, rather
than an inherent requirement for invasion and motility of
the cells. However, the altered growth factor response of
cells exhibiting aberrant E-cadherin expression is likely to
exacerbate the metastatic phenotype leading to cell invasion
and motility, eventually resulting in metastasis of CSCs
exhibiting regulation of E-cadherin from the tumour cell
mass. Clearly, where expression of E-cadherin at a secondary
siteisdetrimentaltoCSCestablishment, thencellsexhibiting
irreversible aberrant E-cadherin expression may successfully
metastasise.
Whilst we have focused on aberrant E-cadherin expres-
sion in the DENT hypothesis, we have not related this
eﬀect to the expression of proteins that regulate this pro-
cess, although these are likely to include the RTK, FGF,
and TGFβ families. Therefore, identiﬁcation of molecules
exhibiting altered expression following aberrant E-cadherin
expression within normal epithelium may provide novel
targets for further experimental investigation. In addition,
themetastatic process, which may involveEMT,isunlikelyto
be similar toES cellEMT dueto alterationsin theunderlying
geneticsofthetumourcells.Therefore,theDENThypothesis
focuses on the eﬀects of aberrant E-cadherin expression
in altering growth factor response, rather than inducing
an EMT event. Since there is little evidence describing
the function of loss of E-cadherin expression alone in
epithelial cells or epithelial-derived tumour cells, we believe
that analysis of the eﬀects of loss of E-cadherin in the
absence of EMT-inducing factors will enhance this ﬁeld of
research.
7.Implicationof the DENT Hypothesisto
CancerTherapies
The DENT hypothesis reinforces the current view that
targeting of CSCs within a tumour cell mass will eliminate
tumorigenic and metastatic potential. However, this alone is
unlikely to suﬃce since dediﬀerentiation of TACs to CSCs
could result in establishment of new TSCNs. Therefore,
a multiple targeted approach for the elimination of cells
within the tumour is likely to be essential. This will requireJournal of Oncology 15
elimination of CSCs and TACs from the tumour, the latter
of which may possess the ability to de-diﬀerentiate to a
CSC phenotype. One possible treatment option for tumour
t h e r a p yi st oi n d u c el o s so fE - c a d h e r i nf u n c t i o ni nt h e
entire tumour cell mass (via soluble E-cadherin extracellular
domain, nAb, or peptide inhibition) to provide a relatively
homogenous population of cells where speciﬁc inhibition
of proliferative pathways associated with the tumorigenic
phenotype can be achieved (e.g., FGF signalling). However,
such an approach will require the identiﬁcation of speciﬁc
pathways within individual tumours, and it is unlikely that
all cells within the tumour mass will respond similarly.
In addition, successful induction of loss of E-cadherin
function in the entire tumour cell population may not be
feasible and raises the concern that such treatment could
intensify the tumorigenic phenotype. Therefore, a better
understanding of signalling pathways which are positively
and negatively regulated by E-cadherin expression may
permit the development of therapeutics capable of targeting
bothCSCsandTACs.Currently,therearenumerousreceptor
antagonist and agonist therapeutic agents for the treatment
of various malignancies. For example, therapeutics include
monoclonal antibodies and small molecules that antagonise
factors expressed by tumour cells and the tumour microen-
vironment. Reagents have been developed to target EGFR
and VEGF signalling cascades, which mediate progression of
colorectalcancers. In addition, targeting ofRTKsusing small
molecule inhibitors has been utilised to mediate colorectal
cancer; both Geﬁtinib and Erlotinib are reversible EGFR
tyrosine kinase inhibitors [110, 111]. Therefore, further elu-
cidationofthesignalling pathwayswithin normalepithelium
and the tumour microenvironment may allow development
of therapeutics to target tumour proliferation on several
fronts.
8.Conclusions
Insummary, we haveshown thatabrogation ofE-cadherin in
ES cells results in altered growth factor response, signiﬁcant
changes in the transcriptome and alterations in membrane
protein localisation, which correlate with events during
tumorigenesis. We have presented the DENT hypothesis to
explain events that may occur during neoplasm formation
and establishment of a tumour cell mass. The DENT
hypothesis presented here exhibits some characteristics of
TOFT in that it relies on interactions between the epithelium
and stromal cells to induce aberrant E-cadherin expression
and subsequent altered growth factor response of epithelial
cells. Furthermore, the hypothesis remains faithful to the
C S C Ha n ds h o u l db ev i e w e da sa na d d i t i o n a lc o m p o n e n t
of this theory that attempts to explain events occurring
during the early stages of neoplasia formation. Our aim has
been to stimulate discussion of the function of aberrant
E-cadherin expression in the early events of tumorigenesis
prior to EMT/metastasis and to highlight that loss of E-
cadherin during this process may not necessarily reﬂect
a requirement for cell motility and invasion. Rather, we
perceive the function of aberrant E-cadherin expression
duringtumorigenesistobeanintegralcomponentoftumour
establishmentaswellasthemetastaticspreadoftumourcells.
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